Mark A. Magnuson, M.D.

Director, Vanderbilt Center for Stem Cell Biology

Featured Publication: 

*Pancreatic Inflammation Redirects Acinar to β Cell Reprogramming. Clayton HW, Osipovich AB, Stancill JS, Schneider JD, Vianna PG, Shanks CM, Yuan W, Gu G, Manduchi E, Stoeckert CJ, Magnuson MA (2016) Cell Rep 17(8): 2028-2041.   
Primary publication · 27851966 (PubMed) · PMC5131369 (PubMed Central)


Category
Page
Record History
Added on June 19, 2014 at 1:53 PM by Ray, Terri
Modified on December 30, 2016 at 8:15 AM by Ray, Terri
Shared with (contributions)
Public: Shared Collection
DRTC: Vanderbilt Diabetes: Prior Featured Investigators Master
 

Mark A. Magnuson, M.D.

Professor of Molecular Physiology and Biophysics
Louise B. McGavock Chair
Professor of Cell and Developmental Biology
Professor of Medicine

Research Overview: 

Directed differentiation and genetic manipulation of embryonic stem cells

Research Description:

We are interested in developing new types of therapies for the treatment of diabetes. This requires a deep understanding of pancreatic beta cell function and development. My laboratory has a long history of developing novel and mouse models using gene targeting and recombinase-mediated cassette exchange (RMCE) strategies, and using these mice to gain important new insights and understanding of the molecular physiology of diabetes. However, better models that more closely mimic the physiology and pathophysiology of human diseases, including type 1 and type 2 diabetes, are needed. Towards this end, we have been developing several novel strategies and methods that will enable us to generate better animal models that more closely model the human.

Research Faculty Profile » 

VUSM Faculty Profile »

PubMed Citations »

Magnuson Lab »

 

*Mark A. Magnuson and Hannah W. Clayton »
Hannah, a graduate student, was the first author of the featured publication.